3-year-data of combined navigated laser photocoagulation (Navilas) and intravitreal ranibizumab compared to ranibizumab monotherapy in DME patients.

/ Publications / 3-year-data of combined navigated laser photocoagulation (Navilas) and intravitreal ranibizumab compared to ranibizumab monotherapy in DME patients.

3-year-data of combined navigated laser photocoagulation (Navilas) and intravitreal ranibizumab compared to ranibizumab monotherapy in DME patients.

Authors: Herold, T. R., Langer, J., Vounotrypidis, E., Kernt, M., Liegl, R., & Priglinger, S. G.
Presented: January 1, 2018
Type: Publications

Conclusion: “Combination of navigated laser and ranibizumab achieved BCVA gains equivalent to anti-VEGF monotherapy. These results could be maintained through month 36. Required injections were 2.0 injections lower in year 1 and further 1.3 times fewer in year 2 and 3 in the combination group compared to monotherapy. Adding navigated laser photocoagulation to intravitreal anti-VEGF therapy may still represent a superior therapeutic approach to DME patients.”

Related publications and webinars

From Minimally Invasive Procedure to Photocoagulation: Personalized retinal care with Navilas® (Japanese)

  • Type:
  • Presented:February 8, 2024
Priv.-Doz. Dr. med. Yoko Miura

On-Demand Webinar: Navilas in der täglichen Praxis

  • Type:
  • Presented:February 1, 2017
Dr. Bernd Fassebender
  • The treatment strategy and selected parameters presented in content listed here are solely the responsibility of the treating ophthalmologist, who is required to be familiar with the most recent literature/guidelines or recommendations, as well as with the usage of the Navilas Laser System according to the current Operator’s Manual.